Comments
Loading...

Roivant Sciences Analyst Ratings

ROIVNASDAQ
Logo brought to you by Benzinga Data
Consensus Rating1
Buy
Highest Price Target1
$23.00
Lowest Price Target1
$10.00
Consensus Price Target1
$16.41

Roivant Sciences Analyst Ratings and Price Targets | NASDAQ:ROIV | Benzinga

Roivant Sciences Ltd has a consensus price target of $16.41 based on the ratings of 12 analysts. The high is $23 issued by Truist Securities on March 25, 2024. The low is $10 issued by SVB Leerink on December 19, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on February 11, 2025, November 13, 2024, and September 19, 2024, respectively. With an average price target of $18 between HC Wainwright & Co., there's an implied 65.82% upside for Roivant Sciences Ltd from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Nov 24
1
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
B of A Securities
Piper Sandler
Goldman Sachs
Deutsche Bank

1calculated from analyst ratings

Analyst Ratings for Roivant Sciences

Buy NowGet Alert
02/11/2025Buy Now65.82%HC Wainwright & Co.
Douglas Tsao53%
$18 → $18ReiteratesBuy → BuyGet Alert
11/13/2024Buy Now65.82%HC Wainwright & Co.
Douglas Tsao53%
$18 → $18ReiteratesBuy → BuyGet Alert
09/19/2024Buy NowCantor Fitzgerald
Louise Chen59%
Reiterates → OverweightGet Alert
09/19/2024Buy Now65.82%HC Wainwright & Co.
Douglas Tsao53%
$18 → $18ReiteratesBuy → BuyGet Alert
09/11/2024Buy Now15.15%B of A Securities
Chi Fong25%
$12 → $12.5MaintainsNeutralGet Alert
09/11/2024Buy Now65.82%HC Wainwright & Co.
Douglas Tsao53%
$18 → $18ReiteratesBuy → BuyGet Alert
09/09/2024Buy NowCantor Fitzgerald
Louise Chen59%
Reiterates → OverweightGet Alert
08/19/2024Buy Now65.82%HC Wainwright & Co.
Douglas Tsao53%
$18 → $18ReiteratesBuy → BuyGet Alert
07/10/2024Buy Now102.67%Piper Sandler
Allison Bratzel65%
$20 → $22MaintainsOverweightGet Alert
06/18/2024Buy NowCantor Fitzgerald
Louise Chen59%
Reiterates → OverweightGet Alert
05/31/2024Buy Now65.82%HC Wainwright & Co.
Douglas Tsao53%
$18 → $18ReiteratesBuy → BuyGet Alert
04/22/2024Buy Now65.82%HC Wainwright & Co.
Douglas Tsao53%
$18 → $18ReiteratesBuy → BuyGet Alert
04/03/2024Buy Now65.82%Goldman Sachs
Corinne Jenkins46%
$16 → $18MaintainsBuyGet Alert
04/03/2024Buy Now65.82%HC Wainwright & Co.
Douglas Tsao53%
$17 → $18MaintainsBuyGet Alert
04/03/2024Buy Now38.19%Deutsche Bank
Neena Bitritto-Garg58%
$14 → $15MaintainsBuyGet Alert
03/25/2024Buy Now111.88%Truist Securities
Robyn Karnauskas56%
→ $23ReiteratesBuy → BuyGet Alert
02/15/2024Buy Now56.61%Wolfe Research
Andy Chen39%
→ $17Initiates → OutperformGet Alert
02/14/2024Buy Now56.61%HC Wainwright & Co.
Douglas Tsao53%
$18 → $17MaintainsBuyGet Alert
01/05/2024Buy Now84.25%Piper Sandler
Allison Bratzel65%
→ $20Initiates → OverweightGet Alert
01/02/2024Buy Now10.55%B of A Securities
Chi Fong25%
$11 → $12MaintainsNeutralGet Alert
12/12/2023Buy Now28.97%Deutsche Bank
Neena Bitritto-Garg58%
→ $14Initiates → BuyGet Alert
11/15/2023Buy Now47.4%Guggenheim
Yatin Suneja49%
$17 → $16MaintainsBuyGet Alert
11/14/2023Buy Now38.19%JP Morgan
Brian Cheng37%
$16 → $15MaintainsOverweightGet Alert
10/17/2023Buy Now56.61%Guggenheim
Yatin Suneja49%
→ $17Initiates → BuyGet Alert
09/27/2023Buy Now47.4%Goldman Sachs
Corinne Jenkins46%
$14 → $16MaintainsBuyGet Alert
09/26/2023Buy Now111.88%Truist Securities
Robyn Karnauskas56%
→ $23ReiteratesBuy → BuyGet Alert
09/18/2023Buy Now38.19%Cantor Fitzgerald
Louise Chen59%
→ $15ReiteratesOverweight → OverweightGet Alert
09/05/2023Buy Now38.19%Cantor Fitzgerald
Louise Chen59%
→ $15ReiteratesOverweight → OverweightGet Alert
08/31/2023Buy Now38.19%Cantor Fitzgerald
Louise Chen59%
→ $15ReiteratesOverweight → OverweightGet Alert
08/22/2023Buy Now38.19%Cantor Fitzgerald
Louise Chen59%
→ $15ReiteratesOverweight → OverweightGet Alert
08/15/2023Buy Now65.82%HC Wainwright & Co.
Douglas Tsao53%
→ $18ReiteratesBuy → BuyGet Alert
07/14/2023Buy Now111.88%Truist Securities
Robyn Karnauskas56%
→ $23ReiteratesBuy → BuyGet Alert
06/29/2023Buy Now65.82%HC Wainwright & Co.
Douglas Tsao53%
$15 → $18MaintainsBuyGet Alert
06/23/2023Buy Now111.88%Truist Securities
Robyn Karnauskas56%
$19 → $23MaintainsBuyGet Alert
06/23/2023Buy Now38.19%HC Wainwright & Co.
Douglas Tsao53%
→ $15ReiteratesBuy → BuyGet Alert
06/20/2023Buy Now38.19%Cantor Fitzgerald
Louise Chen59%
→ $15ReiteratesOverweight → OverweightGet Alert
06/08/2023Buy Now-3.27%B of A Securities
Chi Fong25%
→ $10.5Initiates → NeutralGet Alert
05/18/2023Buy Now28.97%JP Morgan
Brian Cheng37%
$12 → $14MaintainsOverweightGet Alert
05/17/2023Buy Now38.19%HC Wainwright & Co.
Douglas Tsao53%
$14 → $15MaintainsBuyGet Alert
05/12/2023Buy Now28.97%HC Wainwright & Co.
Douglas Tsao53%
→ $14ReiteratesBuy → BuyGet Alert
03/29/2023Buy Now10.55%JP Morgan
Brian Cheng37%
→ $12MaintainsOverweightGet Alert
03/16/2023Buy Now28.97%HC Wainwright & Co.
Douglas Tsao53%
→ $14Reiterates → BuyGet Alert
02/14/2023Buy Now28.97%HC Wainwright & Co.
Douglas Tsao53%
→ $14Reiterates → BuyGet Alert
02/13/2023Buy Now1.34%JP Morgan
Brian Cheng37%
$10 → $11MaintainsOverweightGet Alert
01/19/2023Buy Now1.34%Goldman Sachs
Corinne Jenkins46%
$10 → $11MaintainsBuyGet Alert
01/10/2023Buy Now-7.88%JP Morgan
Brian Cheng37%
$9 → $10MaintainsOverweightGet Alert
01/05/2023Buy Now28.97%Citigroup
Neena Bitritto-Garg58%
$11 → $14MaintainsBuyGet Alert
12/19/2022Buy Now-7.88%SVB Leerink
David Risinger74%
$8 → $10MaintainsOutperformGet Alert
12/12/2022Buy Now-17.09%JP Morgan
Brian Cheng37%
→ $9MaintainsOverweightGet Alert
11/15/2022Buy Now1.34%Citigroup
Neena Bitritto-Garg58%
$10 → $11MaintainsBuyGet Alert
11/15/2022Buy Now-26.3%SVB Leerink
David Risinger74%
$7 → $8MaintainsOutperformGet Alert
08/16/2022Buy Now-7.88%Citigroup
Neena Bitritto-Garg58%
$9 → $10MaintainsBuyGet Alert
06/29/2022Buy Now-35.51%SVB Leerink
David Risinger74%
$6 → $7MaintainsOutperformGet Alert
05/24/2022Buy Now10.55%Goldman Sachs
Corinne Jenkins46%
$15 → $12MaintainsBuyGet Alert
05/23/2022Buy Now-44.73%SVB Leerink
David Risinger74%
→ $6Initiates → OutperformGet Alert
04/29/2022Buy Now38.19%Cantor Fitzgerald
Louise Chen59%
→ $15Initiates → OverweightGet Alert

FAQ

Q

What is the target price for Roivant Sciences (ROIV) stock?

A

The latest price target for Roivant Sciences (NASDAQ:ROIV) was reported by HC Wainwright & Co. on February 11, 2025. The analyst firm set a price target for $18.00 expecting ROIV to rise to within 12 months (a possible 65.82% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Roivant Sciences (ROIV)?

A

The latest analyst rating for Roivant Sciences (NASDAQ:ROIV) was provided by HC Wainwright & Co., and Roivant Sciences reiterated their buy rating.

Q

When was the last upgrade for Roivant Sciences (ROIV)?

A

There is no last upgrade for Roivant Sciences

Q

When was the last downgrade for Roivant Sciences (ROIV)?

A

There is no last downgrade for Roivant Sciences.

Q

When is the next analyst rating going to be posted or updated for Roivant Sciences (ROIV)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Roivant Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Roivant Sciences was filed on February 11, 2025 so you should expect the next rating to be made available sometime around February 11, 2026.

Q

Is the Analyst Rating Roivant Sciences (ROIV) correct?

A

While ratings are subjective and will change, the latest Roivant Sciences (ROIV) rating was a reiterated with a price target of $18.00 to $18.00. The current price Roivant Sciences (ROIV) is trading at is $10.86, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch